hypoactive sexual desire disorder


Also found in: Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to hypoactive sexual desire disorder: Sexual aversion disorder, HSDD

hypoactive sexual desire disorder

n.
A psychological disorder characterized by deficiencies in sexual desire that cause significant distress.
References in periodicals archive ?
Clayton said the causes of HSDD in the study cohort were "biologically based" but that hypoactive sexual desire disorder is a biopsychosocial condition.
In 2015, the FDA approved flibanserin (Addyi) a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist, as the first treatment for hypoactive sexual desire disorder in premenopausal women.
Biopharmaceutical company Palatin Technologies Inc (NYSE MKT:PTN) reported on Monday the receipt of the US Patent and Trademark Office (USPTO) Notice of Allowance for use of Bremelanotide Methods for the treatment of hypoactive sexual desire disorder in premenopausal women.
Hypoactive sexual desire disorder in postmenopausal women: US results from the women's international study of health and sexuality (WISHeS).
In a series of three phase III clinical trials in North America, premenopausal women who met the DSM-IV diagnostic criteria for hypoactive sexual desire disorder (HSDD) and who were in a stable monogamous relationship took flibanserin or placebo.
The deal came one day after the US Food and Drug Administration (FDA) cleared the way for Sprout to market its 'Addyi' pill, which aims to treat a condition known as "acquired, generalised hypoactive sexual desire disorder (HSDD)", or sudden and severe loss of libido among women.
Sprout is focused on treating premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.
The guidelines indicate that postmenopausal women who have been diagnosed with hypoactive sexual desire disorder (little or no interest in sex that is distressing to the woman) may benefit from a trial dose of testosterone taken for three to six months.
Tribulus terrestris in women with hypoactive sexual desire disorder
When associated distress was considered, a survey found the prevalence of hypoactive sexual desire disorder to be 16%, sexual arousal disorder 7%, orgasmic disorder 8%, and dyspareunia 1%.
Despite of women suffering from hypoactive sexual desire disorder reporting boost in sexual desire and reduction in stress with the drugs, the FDA has twice rejected flibanserin since 2010.